![]() | |
Clinical data | |
---|---|
Other names | CGS-25248; ZY-15119 |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C16H18ClN3O3 |
Molar mass | 335.79 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Cebaracetam (INN ; developmental code names CGS-25248; ZY-15119) is an experimental drug of the racetam group described as a nootropic which was never marketed. [1] [2] [3]
It is a chlorinated acetyl piperazine-substituted analogue of phenylpiracetam and is also a derivative of RGPU-95 (4-chlorophenylpiracetam). [4] It is the analogue of RGPU-95 in which the terminal amide group has been replaced with a piperazin-2-one moiety. [4] The mechanism of action of cebaracetam is undefined or unknown. [1]
The drug was under development by Novartis for the treatment of cognition disorders by the 1990s but development was discontinued in 1995. [1] It reached phase 2 clinical trials prior to its discontinuation. [1]